Member of Lyonbiopole
Vaxxel is a preclinical-stage company developing vaccines against the main cause of bronchiolitis and viral pneumonia: human Metapneumovirus (hMPV) and human Respiratory Syncytial Virus (hRSV)
Vaxxel develops intranasal live-attenuated vaccines (LAVs) derived from a proprietary technology based on (i) a genetically modified hMPV developed by the Virology Laboratory of Lyon University and (ii) on a GMP grade Vero cell line permissive to hMPV
Two vaccine-candidates are in development with expected higher and longer protection, addressing a market of >$5bn: a monovalent hMPV vaccine with preclinical PoC, and a first-in-class bivalent hMPV-hRSV vaccine with preclinical PoC
Vaxxel aims to start clinical trials for one of its two first-in-class vaccine candidates by Q2 2024 and is is preparing for a Series A funding round of 10m€ in Q1 2023
Strategic application domain: Human Medicine
Application market: Infectious Diseases, Pneumology - Respiratory Diseases
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Molecular Biology & Nucleic acid, Vaccine
Created on sept. 10th, 2019 - 3 employees
Address
43, Boulevard du 11 Novembre 1918, L’Atrium 69100 Villeurbanne
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.